We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
They are talking about an oral version of Wegovy/Ozempic, which could be huge if they can improve upon the bioavailability of extant formulations.
I think I know the reason for the current weakness in the share price. Downing LLP are closing down and as such liquidating their positions. The last I saw was that they held just over 5% of Arecor, but that was from over a year ago and they have been selling for some time now. I do not know how many they have left, but I believe this is an opportunity to either add or take a position in the company at, in my opinion, bargain basement prices. I do not believe the share would be at current levels but for this special situation.
I bought 9,000 @ 166.88 just after opening, not showing ...
I have no idea why, but there must be a large seller. All the volume in recent days have been buys...I bought some this morning, but the price is not moving. Time was that it was v illiquid, but I think at least 25k has been bought over the week and the price has not moved.
Sanofi to acquire INBRX-101 for up to $2.2 billion.
hxxps://www.prnewswire.com/news-releases/inhibrx-announces-sale-of-inbrx-101-to-sanofi-for-an-aggregate-value-of-up-to-2-2b-302041424.html
News or no News, named partners or not, this share price is not for moving.... I guess the company will have to show good figures in its financials before the world wakes up, responds etc.
The diabetes treatment grabs all of the headlines but there is a lot more to the company than just this.
Sounds very interesting, will it attract a takeover bid?
Market has again failed to react to good news from the company. Hopefully they will get further exposure at the diabetes conference in the US. If the market continues to ignore this company surely it must become a potential takeover target?
Our highly innovative formulation technology addresses these challenges and, when applied, we are able to develop enhanced novel pharmaceutical products, both for our growing partnerships with Pharma companies and in our proprietary pipeline. This US patent is a very important addition to our IP portfolio, protecting a formulation design space that enables monoclonal antibodies with superior stability.
Sounds good to me!
:-)
In case you missed our webinar with Arecor Therapeutics plc (AREC) earlier this month, the recording can be found on our YouTube channel: https://youtu.be/UjdNjbBBWdw
Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal
https://www.reuters.com/markets/deals/frances-sanofi-acquire-us-based-provention-bio-29-bln-2023-03-13/
https://www.thisismoney.co.uk/money/investing/article-11847771/MIDAS-SHARE-TIPS-dose-profits-diabetes-jabs-Arecor.html?ico=mol_desktop_money-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.co.uk%2Fmoney%2Findex.html&_ga=2.81489175.1643311655.1678573927-1843241439.1674940599&_gl=1*gp4448*_ga*MTg0MzI0MTQzOS4xNjc0OTQwNTk5*_ga_XE0XLFFF16*MTY3ODU3MzkyNi41LjEuMTY3ODU3Mzk2MS4wLjAuMA..
I missed it. What were the key takeaways?
I thought they sounded very credible and they clearly have a plan. Letβs see what the next 12 months bring.
ShareSoc is hosting a webinar with Arecor Therapeutics plc (AREC) on 07 March 2023, which may be of interest to current shareholders or potential investors. Sarah Howell Ph.D (Chief Executive Officer) and Susan Lowther (Chief Financial Officer) will be presenting. You can register here: hTTps://www.sharesoc.org/events/sharesoc-webinar-with-arecor-therapeutics-plc-arec07-march-2023/
Sorry, a little under 1% of the company,
A large trade went through at 3:24pm. More than 2.1% of the company.
Almost alone. A good outcome with Hikma, but we wont know for a while how significant this is in monetary terms.
Not alone sir!
Am I here all in my own? ;-)
RNS - positive news!